Skip to content

Observational Study of Objective Response Rate to Ivonescimab Combined with Chemotherapy in Patients with Locally Advanced Resectable Oral and Oropharyngeal Squamous Cell Carcinoma

Observational Study of Objective Response Rate to Ivonescimab Combined with Chemotherapy in Patients with Locally Advanced Resectable Oral and Oropharyngeal Squamous Cell Carcinoma

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600117410
Enrollment
Unknown
Registered
2026-01-23
Start date
2026-02-01
Completion date
Unknown
Last updated
2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

locally advanced resectable oral squamous cell carcinoma and oropharyngeal squamous cell carcinoma

Interventions

Observation group:None

Sponsors

Zhujiang Hospital of Southern Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Pathological diagnosis of oral squamous cell carcinoma or oropharyngeal squamous cell carcinoma; 2. According to AJCC criteria (8th edition), diagnosed with locally advanced disease (stage III/IVA oral cancer or HPV-negative oropharyngeal cancer, stage II/III HPV-positive oropharyngeal cancer) and assessed by the investigator as surgically resectable; 3. Age 18-80 years; 4. Blood routine: white blood cell count >= 3×10^9/L, platelet count >= 75×10^9/L; hemoglobin concentration >= 80 g/L; 5. Liver function: AST and ALT 50 ml/min; 7. Major organs such as heart, lungs, thyroid, and overall condition capable of tolerating the study treatment regimen; 8. Signed informed consent.

Exclusion criteria

Exclusion criteria: 1.Pregnancy or lactation (for female participants); 2.A history of epilepsy or mental illness that is not effectively controlled; 3.Unresolved toxicities of grade > 2 per CTCAE criteria resulting from prior anticancer therapy; 4.Other conditions deemed unsuitable for study participation by the investigators, including patients with autoimmune diseases or those at high risk of bleeding due to various causes.

Design outcomes

Primary

MeasureTime frame
Objective Response Rate,ORR;

Secondary

MeasureTime frame
two-year event-free survivall rate;Tumor regression pattern;

Countries

China

Contacts

Public ContactLv Xiaozhi

Zhujiang Hospital of Southern Medical University

lxzsurgeon@126.com+86 20 62782092

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026